Better Patient Care Through Innovation

 

Available Now

Now available by prescription, SYNDROS® (dronabinol) oral solution is the first and only liquid dronabinol approved by the FDA.

Read More

About INSYS

Our vision is to improve the quality of patient care by building a specialty pharmaceutical company focused on cannabinoids and novel drug delivery systems that address unmet patient needs.

SCIENCE

We are an innovative organization with a focus on providing therapeutic solutions helping to improve the lives of patients. 

 

SCIENCE

We are an innovative organization with a focus on providing therapeutic solutions helping to improve the lives of patients. 

 

SOCIAL RESPONSIBILITY

Our commitment to better patient care is measured not only by our focus on bringing innovative technologies to patients and physicians, but also by the importance we place on making an impact within the communities where we work and live.

 

SOCIAL RESPONSIBILITY

Our commitment to better patient care is measured not only by our focus on bringing innovative technologies to patients and physicians, but also by the importance we place on making an impact within the communities where we work and live.

 

Recent News

INSYS Therapeutics to Present at J.P. Morgan Healthcare Conference

Recent News

FDA Grants INSYS Therapeutics ‘Fast Track’ Designation for Cannabidiol (CBD) Oral Solution as Investigational Treatment for Prader-Willi Syndrome

Recent News

INSYS Therapeutics Initiates Phase 2 Clinical Trial of Cannabidiol (CBD) Oral Solution for Treatment of Refractory Childhood Absence Epilepsy in Pediatric Patients